Document Detail


Clinical experience with somatrem in Japan.
MedLine Citation:
PMID:  3296635     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A total of 62 patients with pituitary dwarfism were treated with three different preparations of human growth hormone (hGH) produced by recombinant DNA technology (somatrem). They were given somatrem, 0.5 IU/kg body weight/week for 3-14 months. Their height velocity increased from 3.5 +/- 0.9 to 8.2 +/- 1.7 cm/year (mean +/- SEM) during treatment. There were no significant changes in physical, blood and urine examinations. Anti-hGH antibody was observed in 39 of 62 patients (62.9%) at the end of 3 months of treatment with three different preparations of somatrem and in 16 of 21 patients (76.2%) at the end of 12 months of treatment with highly purified Somatonorm. The presence of antibody to hGH did not affect the growth rate in 48 of 49 hGH deficient children who had measurable antibody.
Authors:
K Takano; K Shizume
Related Documents :
24327125 - Conclusiveness of the cochrane reviews in nutrition: a systematic analysis.
19258715 - Long-acting lanreotide in adolescent girls with constitutional tall stature.
18209875 - Criteria of cure and remission in cushing's disease: an update.
19844125 - Seven years of safety and efficacy of the recombinant human growth hormone omnitrope in...
1450475 - Current functional status of symbion total artificial heart recipients after transplant...
18639095 - Natural history of arteriovenous malformations: analysis of non-radically treated patie...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acta paediatrica Scandinavica. Supplement     Volume:  325     ISSN:  0300-8843     ISO Abbreviation:  Acta Paediatr Scand Suppl     Publication Date:  1986  
Date Detail:
Created Date:  1987-07-21     Completed Date:  1987-07-21     Revised Date:  2008-02-20    
Medline Journal Info:
Nlm Unique ID:  0173166     Medline TA:  Acta Paediatr Scand Suppl     Country:  SWEDEN    
Other Details:
Languages:  eng     Pagination:  19-24     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antibody Formation
Child
Child, Preschool
Clinical Trials as Topic
Dwarfism, Pituitary / drug therapy*,  immunology,  pathology
Growth / drug effects
Growth Hormone / adverse effects,  analogs & derivatives*,  immunology,  therapeutic use
Human Growth Hormone
Humans
Japan
Chemical
Reg. No./Substance:
12629-01-5/Human Growth Hormone; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of pituitary dwarfism with biosynthetic growth hormone.
Next Document:  Clinical experience of somatrem: UK preliminary report.